RARE ALERT: Motif Bio said to have kicked off $3 million equity fundraising - sources
Motif Bio, a clinic stage biopharmaceutical company, is tapping investors for up to $3 million.
People claiming to be familiar with the situation said Motif Bio is looking to raise the fresh capital at a 25pc discount to last Friday's opening price.
The proceeds from the equtiy fundraising will be used as working capital, said people claiming to be familiar with the matter.
Motif Bio, whose shares are also listed on the Nasdaq, is focused on developing novel antibiotics designed to be effective against serious and life-threatening infections...
Register for free to see rest of this article and all public articles from BetavilleLogin / Register